The Efficacy of Cranial-electrotherapy Stimulation (CES) Using Alpha-Stim Technology in The Treatment of Anxiety Disorders
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 115
- 试验地点
- 4
- 主要终点
- Anxiety symptoms as reported on the Hamilton Anxiety Rating Scale
研究概览
简要总结
Is CES effective in the treatment of anxiety when accounting for any comorbid conditions and or current treatments including medication and psychotherapy.
详细描述
The goal of this study is to evaluate the efficacy of Alpha-Stim technology in the treatment of anxiety by using a double-blind clinical trial over a period of five weeks. Cranial-electrotherapy stimulation (CES) is a noninvasive procedure that has been used for decades in the United States to treat anxiety, depression, and insomnia. Although many studies on CES have been published in previous decades, most have used relatively small samples using various frequencies and links of treatment. Given the positive results of the many general studies that have been performed to date, this study seeks to add to the current literature by addressing previous criticisms using a large sample size (n=150)and using participants that represent more than a single type of anxiety along with comorbidity. Such a population is believed to better represent typical treatment complications.
Participants will be recruited via advertisements in a local newspaper and posting of flyers around a local university campus. Participants will be screened through an intake process using the Structured Clinical Interview for Axis I Disorders (SCID-I) to confirm a diagnosis of an anxiety disorder. Comorbid conditions are acceptable, however, an anxiety disorder must be the primary diagnosis. As part of the intake process, participants will complete the Hamilton Anxiety Rating Scale (HAM-A)and the Hamilton Depression Rating Scale (HAM-D17) to establish a baseline. These instruments will serve as the primary efficacy measures. In order to participate, HAM-A scores must equal to or greater than 18 (Moderate Anxiety). Depression will be monitored using The HAM-D17 as depression is a commonly occurring condition with anxiety and the HAM-D17 is also sensitive to anxiety. Current treatment with medications are also acceptable provided there will be no changes in dosage or type during the study. See Inclusions and Exclusions for further information. All participants will pay a fee of $30 to enter the study to cover administration costs and as a way to measure placebo effect. Participants will be assigned a device to take home and self-administer treatment 5-7 days a week. Participants will be required to log their treatment times and dates with logs provided by the researcher. The student population will not be given a take home device but will receive treatment at the Graduate Assistant's Office or Student Care Office.
Electromedical Products International, Inc. has agreed to supply the devices needed to carry out the research to include conductance solution, felt tabs, and batteries. Half of the devices will be set by the manufacturer to deliver treatment at 0.5 Hz and at the lowest therapeutic setting. The remaining devices will be shame and not deliver any therapeutic benefit. The devices will not be able to be altered by the participant.
Participants will meet with the PI or research assistant to complete the HAM-A and HAM-D17 at weeks 1, 3, and 5 at a designated location either in the researchers private practice office or university lab location. Adverse treatment reactions will also be noted. Treatment logs will also be collected at these points. At weeks 1 and 3, participants will be given fresh batteries, conductance solution, and felt tabs as needed. At the completion of the study, participants found to be in the shame treatment group will be offered the normal course of treatment. Participants not wanting to continue the study or do not wish to follow through with normal treatment after being in the shame group will be refunded their fee.
The hypothesis this study seeks to address is:
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The subject is male or female outpatients age 18 to 65 years.
- •The subject meets DSM-IV criteria for an anxiety disorder.
- •Participants with comorbidity must carry an anxiety disorder as a primary diagnosis.
- •Written informed consent must be obtained from the subject prior to study participation.
- •The subject is in good medical health or with chronic medical conditions which are currently stable.
- •No current abuse of alcohol or other substance.
- •The subject has a total score greater than 15 on the Beck Anxiety Inventory and a score greater than 45 on the Zung Self Report Anxiety Scale.
排除标准
- •The subject meets DSM-IV criteria for an Axis I diagnosis (other than an Anxiety Disorder) as the primary diagnosis (i.e., schizophrenia, mood disorder, psychosis, anorexia nervosa).
- •The subject is clinically judged by the investigator to be at risk for suicide or is acutely suicidal.
- •The subject is clinically judged by the investigator to be at risk for homicide or is acutely homicidal.
- •The subject has a psychiatric condition that would require inpatient, or partial psychiatric hospitalization.
- •Seizure disorders.
- •Significant history of medical disease (i.e. cardiovascular, hepatic (e.g. cirrhosis, hepatitis B or C) renal, gynecological, musculoskeletal, neurological, gastrointestinal, metabolic, hematological, endocrine, cancer with a metastatic potential or progressive neurological disorders) which could impair reliable participation in the trial or necessitate the use of medication not allowed by this protocol.
- •Use of a pacemaker.
- •The subject is pregnant, planning to become pregnant, or nursing. If a subject becomes pregnant, she will be discontinued immediately and followed appropriately.
- •Current psychotherapeutic treatment except for treatment with Specific Reuptake Inhibitor (SSRIs) medications which include: Fluoxetine (Prozac), Paroxetine (Paxil), Sertraline (Zoloft), Luvox (Fluvoxamine), Citalopram. Potential subjects may remain on their medications provided that he or she has been on a stable dose prior to entering this study; the dose and type of medication remains stable throughout the remainder of this study; and it can be determined that this medication is not exacerbating the anxiety symptoms.
- •History of poor compliance or in the Investigator's judgment patients any subject whose treatment as an outpatient would be clinically contraindicated
- •The subject has attempted suicide one or more times within the past twelve months
结局指标
主要结局
Anxiety symptoms as reported on the Hamilton Anxiety Rating Scale
时间窗: Change from Baseline in Hamilton Anxiety Rating Scale scores assessed at different points, e.g., Week 1, Week 3, and Week 5.
The HAM-A was one of the first rating scales developed to measure the severity of anxiety symptoms, and is still widely used today in both clinical and research settings. The scale consists of 14 items, each defined by a series of symptoms, and measures both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints related to anxiety). Scores range of 0-56, where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe.
Depression symptoms as reported on the Hamilton Depression Rating Scale 17
时间窗: Change from Baseline in Hamilton Depression Rating Scale 17 scores assessed at different points, e.g., Week 1, Week 3, and Week 5.
The Hamilton Depression Scale is a test measuring the severity of depressive symptoms in individuals. It is often used as an outcome measure of depression in research. In the 17-item version, nine of the items are scored on a five-point scale, ranging from zero to four. The remaining eight items are scored on a three-point scale. For the 17-item version, scores can range from 0 to 54. 0 and 6 indicate a normal person with regard to depression, scores between 7 and 17 indicate mild depression, scores between 18 and 24 indicate moderate depression, and scores over 24 indicate severe depression.
次要结局
未报告次要终点
研究者
Tim Barclay
Asst. Professor
Wyndhurst Counseling Center